KPV
Lysine-Proline-Valine
Last updated: April 26, 2026
Also known as: Lys-Pro-Val, α-MSH(11–13), C-terminal tripeptide of alpha-MSH
What It Is
If you have a chronic inflammatory or gut condition and someone mentioned KPV, here’s what you need to know.
KPV is a tripeptide — three amino acids: lysine, proline, and valine. It’s the smallest fragment of alpha-MSH (alpha-melanocyte-stimulating hormone), a peptide your body produces naturally to regulate inflammation and immune response. Researchers found that the entire anti-inflammatory effect of alpha-MSH is concentrated in this three-amino-acid tail — KPV by itself retains the inflammation-suppressing properties without the pigment-stimulating effects of the full molecule.
KPV works by binding to melanocortin receptors (MC1R and MC3R) on immune cells, reducing pro-inflammatory cytokines like TNF-alpha, IL-1, and IL-6. These are the same pathways targeted by biologic drugs for ulcerative colitis and Crohn’s — through a different receptor system. Most studied for inflammatory bowel conditions, but research has also examined skin inflammation, wound healing, and antimicrobial activity. As of 2026, no large human clinical trials have been completed.
What Does the Research Actually Show?
Inflammatory Bowel Disease & Ulcerative Colitis
T2: Emerging EvidenceMultiple animal models of colitis show KPV reduces inflammation scores, decreases pro-inflammatory cytokines, and accelerates mucosal healing. Replicated across multiple research groups. One small human pilot study in active ulcerative colitis (under 30 patients, 8 weeks, not placebo-controlled) showed reduced inflammatory markers and symptom improvement. KPV is most effective when delivered orally or rectally rather than systemically — its small size resists GI degradation. This is the use case the FDA flagged for the July 2026 PCAC review.
General Anti-Inflammatory Effects
T3: Early / AnecdotalAnimal data across arthritis, allergic airway inflammation, and contact dermatitis models. Mechanism is the same as for IBD applications. Human data outside the gut is essentially absent.
Topical Wound Healing & Skin Inflammation
T3: Early / AnecdotalAnimal studies and case reports suggest topical KPV may accelerate wound closure and reduce inflammation in conditions like atopic dermatitis. Some compounding pharmacies offer it as a topical cream or serum. Bioavailability and formulation quality data are limited.
Antimicrobial Activity
T3: Early / AnecdotalIn vitro activity against several pathogens including Candida albicans and certain gram-positive bacteria. Whether this translates to clinical antimicrobial benefit in humans is unknown.
It’s worth noting: without controlled human trials at scale, we can’t rule out that practitioner-reported benefits are placebo or coincidental with other interventions. The mechanistic rationale for KPV is among the strongest of any T2 compound — but sound rationale isn’t proof.
How Is KPV Administered?
| Route | Oral capsule (most evidence for IBD), rectal suppository, subcutaneous injection, topical |
| Dosage Range | 200–500 mcg |
| Frequency | 1–2x daily |
| Cycle Length | 4–8 week courses, with reassessment |
| Time to Effect | 2–6 weeks (inflammatory conditions) |
| Note | Your provider determines the right protocol. Do not self-dose. |
Protocols vary by individual. Always follow your prescribing provider's instructions.
For injection supplies and self-administration basics, see our Injectable Peptide Supplies Guide →
What Are the Side Effects and Risks?
- Mild GI symptoms (oral use, usually transient).
- Injection site irritation (subcutaneous use).
- Headache (uncommon).
- Limited human safety data means unknown long-term risks.
- Pregnancy and breastfeeding are absolute contraindications.
- Long-term effects on immune regulation are not well understood.
Who Should NOT Use KPV?
If you have an active autoimmune condition managed with biologics or other immunosuppressants: KPV’s anti-inflammatory mechanism overlaps significantly with biologic drugs that target TNF-alpha, IL-1, and IL-6. Layering an unstudied peptide on top of a biologic — without coordinated specialist oversight — creates an interaction profile no one has data on. Your prescribing rheumatologist or gastroenterologist must be in the loop. “My peptide provider said it’s fine” is not coordination.
If you have a melanoma history or active melanoma: KPV acts on melanocortin receptors. The role of these receptors in melanoma biology is not well characterized, and no human studies have evaluated KPV in patients with melanoma history. The cautious default in this situation is avoidance until that data exists.
If you are pregnant or breastfeeding: No safety data exists. This is not a situation where “probably fine” is an acceptable standard.
If you have inflammatory bowel disease and have not seen a gastroenterologist: KPV is not a substitute for specialist diagnosis and care. IBD requires monitoring for complications — strictures, fistulas, dysplasia, malabsorption — that no peptide protocol addresses. If your gastroenterologist is willing to incorporate KPV into your overall plan, that’s one thing. Skipping the specialist entirely is another.
If you have GI symptoms but no clear diagnosis: KPV won’t fix the wrong diagnosis. Chronic gut symptoms can be IBD, IBS, SIBO, celiac, food intolerances, parasites, structural conditions, or any combination. The workup matters more than the peptide. Starting an anti-inflammatory therapy before you know what you’re treating can mask symptoms while the underlying problem progresses.
If you are self-sourcing from unregulated vendors: KPV was removed from Category 2 effective April 22, 2026 but is not yet legal to compound — PCAC review is scheduled for July 23, 2026 and a final FDA rule must follow before compounding can resume. If you’re buying KPV from a “research peptide” website, you have no assurance of purity, sterility, or dosing accuracy. Independent testing of gray-market peptides has found contamination, mislabeling, and in some cases no active compound at all.
The general principle: KPV has the strongest mechanistic case of any peptide on the July 2026 PCAC agenda, and the human evidence base is concentrated in a serious indication (ulcerative colitis). It is not a proven therapeutic with established safety boundaries. Fewer than 100 humans have been studied in published trials. If you’re using it, you are accepting a level of uncertainty — and the minimum responsible behavior is to do so with a licensed provider who has your complete medical history, including current diagnoses, medications, and any specialist care.
Is KPV Legal in 2026?
Not FDA-approved. Removed from Category 2 effective April 22, 2026. PCAC review scheduled for July 23, 2026 — KPV is on the agenda alongside BPC-157, TB-500, and MOTS-C, with the FDA reviewing it for “wound healing and inflammatory conditions.” Compounding cannot resume until after PCAC review and a final FDA determination adds KPV to the 503A bulks list. If approved, it will be available via prescription through licensed compounding pharmacies — it will NOT be available over the counter or FDA-approved. The FDA accepts public comments through Docket FDA-2025-N-6895. Comments received by July 9, 2026 will be provided to the committee.
This compound’s legal status is actively evolving. Get updates when it changes →
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include CBC, CMP, CRP (C-reactive protein), and ESR (inflammatory markers). For gut applications, also consider fecal calprotectin, vitamin D, B12, and an iron panel.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Order at-home labs from Everlywell →Lab recommendations are the same regardless of which service you use. See how we make money.
What You'll Need
If your provider prescribes an injectable protocol, you'll need basic supplies.
- Bacteriostatic Water (30ml)Link coming soon
- Insulin Syringes 29 gauge (100ct)Link coming soon
- Alcohol Prep Pads (200ct)Link coming soon
- Sharps ContainerLink coming soon
Supply links are affiliate links. We may earn a commission at no cost to you. We only link to commodity supplies, never to peptide products. See how we make money.
Questions for Your Provider
- 1Based on my specific condition, is KPV appropriate, or would established treatment be a better starting point?
- 2Which administration route do you recommend for me, and why? (Oral for IBD applications has the most evidence support.)
- 3What’s the current compounding availability for KPV given the post-Category 2 / pre-PCAC limbo? On what legal basis is your pharmacy filling these prescriptions?
- 4If I’m currently on a biologic or immunosuppressant, how does KPV interact, and have you coordinated with my specialist?
- 5What baseline labs do you want me to complete before starting? How will we measure response?
- 6Which compounding pharmacy do you use, and is it 503A or 503B?
- 7What does success look like, and at what point would we conclude KPV isn’t working?
How Do I Get KPV Through a Legitimate Provider?
These providers meet our evaluation criteria: verified medical license, labs required before prescribing, and medications sourced from licensed U.S. pharmacies.
Peter MD
Hormone optimization, peptides, and longevity. Labs required before prescribing.
Not available in ID, AL. Lab work not available in NY, NJ, RI.
Book a ConsultationWe continuously evaluate providers. New additions will appear here as they’re verified.
These are affiliate links. We may earn a commission if you book through them. This never influences our evidence ratings or recommendations. See how we make money.